ONC201 for Brain Tumor
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests ONC201, a new type of treatment that has shown promise in fighting various cancers, including a specific type of brain cancer, in patients who have this cancer returning.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but it does mention that you cannot use certain drugs that affect liver enzymes (CYP3A4/5 inhibitors and inducers) during the study and shortly before starting it. It's best to discuss your current medications with the study team to see if any adjustments are needed.
What makes the drug ONC201 unique for treating brain tumors?
ONC201 is unique because it targets a specific pathway in cancer cells, potentially offering a new approach for treating brain tumors that are resistant to standard therapies. Unlike other treatments, it may work by inducing stress in tumor cells, leading to their death, and is being explored for its effectiveness in various types of brain tumors.12345
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 625 mg oral dordaviprone (ONC201) every 1 or 3 weeks depending on the arm, with clinical evaluations after each cycle
Neuroimaging
Neuroimaging studies are performed at baseline, 8 weeks from treatment initiation, and then every 8 weeks thereafter
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ONC201
Find a Clinic Near You
Who Is Running the Clinical Trial?
Chimerix
Lead Sponsor
Oncoceutics, Inc.
Industry Sponsor